#METABOLOMICS WORKBENCH michaelsa93_20170809_135138 DATATRACK_ID:1197 STUDY_ID:ST000846 ANALYSIS_ID:AN001369 PROJECT_ID:PR000600 VERSION 1 CREATED_ON August 10, 2017, 2:57 pm #PROJECT PR:PROJECT_TITLE Statin Immuno-Metabolomics in Asthma PR:PROJECT_SUMMARY Innovative and novel therapies are urgently needed for the treatment of patients PR:PROJECT_SUMMARY with severe asthma, especially those who are refractory to standard-of-care PR:PROJECT_SUMMARY bronchodilators and inhaled corticosteroids. The Zeki lab is investigating the PR:PROJECT_SUMMARY role of the mevalonate (MA) pathway, in the pathogenesis of airway inflammation PR:PROJECT_SUMMARY and remodeling. Although statins all inhibit HMGCR in the same manner in terms PR:PROJECT_SUMMARY of enzyme binding site, the statins’ varied physiochemical properties with PR:PROJECT_SUMMARY respect to their polarity (i.e. lipophilicity) result in very different immune PR:PROJECT_SUMMARY and lipid effects. The major significance of this work is to advance a new class PR:PROJECT_SUMMARY of inhaler therapies for asthma; the statins which work by an entirely different PR:PROJECT_SUMMARY mechanism than current ICS/LABA mainstays. Evidence suggests that statins may PR:PROJECT_SUMMARY have an additive benefit to corticosteroids in asthma, thereby confirming a PR:PROJECT_SUMMARY unique mechanism, namely via MVA pathway inhibition. This becomes particularly PR:PROJECT_SUMMARY important in the severe asthma population which is highly PR:PROJECT_SUMMARY corticosteroid-resistant, is poorly controlled with high exacerbation rates and PR:PROJECT_SUMMARY hospitalizations, and has the highest healthcare costs of all asthma phenotypes. PR:PROJECT_SUMMARY In essence, the potential public health impact of even an incremental PR:PROJECT_SUMMARY improvement in asthma symptom control cannot be underestimated. Even the PR:PROJECT_SUMMARY prevention of 1 asthma attack preserves lung function and reduces the adverse PR:PROJECT_SUMMARY personal and financial impact. This study aimed to determine if statin polarity PR:PROJECT_SUMMARY affects airway drug concentration and systemic drug absorption and to determine PR:PROJECT_SUMMARY the effect of inhaled statins on naïve airway immune cell populations and PR:PROJECT_SUMMARY alveolar-capillary membrane and epithelial barrier integrity in healthy rhesus PR:PROJECT_SUMMARY monkeys. In this particular component of the study, we investigated the PR:PROJECT_SUMMARY metabolic effects resulting from the use of statins in these healthy rhesus PR:PROJECT_SUMMARY monkeys. Specifically, the Newman lab analyzed for lipid mediator (oxylipin, PR:PROJECT_SUMMARY endocannabinoid, fatty acid, and nitro lipid) in lung and trachea tissue, PR:PROJECT_SUMMARY plasma, and BAL and bile acid changes in the lung and trachea tissue and plasma. PR:INSTITUTE University of California, Davis PR:DEPARTMENT Internal Medicine PR:LAST_NAME Zeki PR:FIRST_NAME Amir PR:ADDRESS 2825 J St. Suite 400 Sacramento, CA 95816 PR:EMAIL aazeki@ucdavis.edu PR:PHONE (916) 734-8230 #STUDY ST:STUDY_TITLE Statin Immuno-Metabolomics in Asthma (part IV) ST:STUDY_TYPE Placebo-controled trial ST:STUDY_SUMMARY Innovative and novel therapies are urgently needed for the treatment of patients ST:STUDY_SUMMARY with severe asthma, especially those who are refractory to standard-of-care ST:STUDY_SUMMARY bronchodilators and inhaled corticosteroids. The Zeki lab is investigating the ST:STUDY_SUMMARY role of the mevalonate (MA) pathway, in the pathogenesis of airway inflammation ST:STUDY_SUMMARY and remodeling. Although statins all inhibit HMGCR in the same manner in terms ST:STUDY_SUMMARY of enzyme binding site, the statins’ varied physiochemical properties with ST:STUDY_SUMMARY respect to their polarity (i.e. lipophilicity) result in very different immune ST:STUDY_SUMMARY and lipid effects. The major significance of this work is to advance a new class ST:STUDY_SUMMARY of inhaler therapies for asthma; the statins which work by an entirely different ST:STUDY_SUMMARY mechanism than current ICS/LABA mainstays. Evidence suggests that statins may ST:STUDY_SUMMARY have an additive benefit to corticosteroids in asthma, thereby confirming a ST:STUDY_SUMMARY unique mechanism, namely via MVA pathway inhibition. This becomes particularly ST:STUDY_SUMMARY important in the severe asthma population which is highly ST:STUDY_SUMMARY corticosteroid-resistant, is poorly controlled with high exacerbation rates and ST:STUDY_SUMMARY hospitalizations, and has the highest healthcare costs of all asthma phenotypes. ST:STUDY_SUMMARY In essence, the potential public health impact of even an incremental ST:STUDY_SUMMARY improvement in asthma symptom control cannot be underestimated. Even the ST:STUDY_SUMMARY prevention of 1 asthma attack preserves lung function and reduces the adverse ST:STUDY_SUMMARY personal and financial impact. This study aimed to determine if statin polarity ST:STUDY_SUMMARY affects airway drug concentration and systemic drug absorption and to determine ST:STUDY_SUMMARY the effect of inhaled statins on naïve airway immune cell populations and ST:STUDY_SUMMARY alveolar-capillary membrane and epithelial barrier integrity in healthy rhesus ST:STUDY_SUMMARY monkeys. In this particular component of the study, we investigated the ST:STUDY_SUMMARY metabolic effects resulting from the use of statins in these healthy rhesus ST:STUDY_SUMMARY monkeys. Specifically, the Newman lab analyzed for lipid mediator (oxylipin, ST:STUDY_SUMMARY endocannabinoid, fatty acid, and nitro lipid) in lung and trachea tissue, ST:STUDY_SUMMARY plasma, and BAL and bile acid changes in the lung and trachea tissue and plasma. ST:INSTITUTE USDA ST:DEPARTMENT Obesity and metabolism research unit ST:LABORATORY Newman's Lab ST:LAST_NAME Newman ST:FIRST_NAME John ST:ADDRESS 430 West Health Sciences Dr. Davis, Ca, 95616 ST:EMAIL John.Newman@ars.usda.gov ST:PHONE (530) 752-1009 #SUBJECT SU:SUBJECT_TYPE Animal SU:SUBJECT_SPECIES Macaca mulatta SU:TAXONOMY_ID 9544 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS - Zeki R 74 Tissue:Right Lung | Treatment:Control SUBJECT_SAMPLE_FACTORS - Zeki R 28 Repl Avg. Tissue:Right Lung | Treatment:Control SUBJECT_SAMPLE_FACTORS - Zeki R 48 Tissue:Right Lung | Treatment:Control SUBJECT_SAMPLE_FACTORS - Zeki R 68 Tissue:Right Lung | Treatment:Simvastatin SUBJECT_SAMPLE_FACTORS - Zeki R 40 Tissue:Right Lung | Treatment:Simvastatin SUBJECT_SAMPLE_FACTORS - Zeki R 95 Tissue:Right Lung | Treatment:Simvastatin SUBJECT_SAMPLE_FACTORS - Zeki L 74 Tissue:Left Lung | Treatment:Control SUBJECT_SAMPLE_FACTORS - Zeki L 48 Tissue:Left Lung | Treatment:Control SUBJECT_SAMPLE_FACTORS - Zeki L 28 Repl Avg. Tissue:Left Lung | Treatment:Control SUBJECT_SAMPLE_FACTORS - Zeki L 95 Tissue:Left Lung | Treatment:Simvastatin SUBJECT_SAMPLE_FACTORS - Zeki L 40 Tissue:Left Lung | Treatment:Simvastatin SUBJECT_SAMPLE_FACTORS - Zeki L 68 Tissue:Left Lung | Treatment:Simvastatin SUBJECT_SAMPLE_FACTORS - Zeki T 74 Tissue:Trachea | Treatment:Control SUBJECT_SAMPLE_FACTORS - Zeki T 48 Tissue:Trachea | Treatment:Control SUBJECT_SAMPLE_FACTORS - Zeki T 28 Repl Avg. Tissue:Trachea | Treatment:Control SUBJECT_SAMPLE_FACTORS - Zeki T 40 Tissue:Trachea | Treatment:Simvastatin SUBJECT_SAMPLE_FACTORS - Zeki T 68 Tissue:Trachea | Treatment:Simvastatin SUBJECT_SAMPLE_FACTORS - Zeki T 95 Tissue:Trachea | Treatment:Simvastatin #COLLECTION CO:COLLECTION_SUMMARY Monkeys were treated with placebo or Provastatin for 12 days. Further, after the CO:COLLECTION_SUMMARY wash out period animals were treated with Simvastatin for 12 days. Tissue were CO:COLLECTION_SUMMARY collected upone animals termination at day 12 of Simvastatin treatment CO:SAMPLE_TYPE Tissue CO:TISSUE_CELL_IDENTIFICATION Trachea and lung tissue #TREATMENT TR:TREATMENT_SUMMARY Monkeys were treated (by inhalation) with placebo or Provastatin for 12 days. TR:TREATMENT_SUMMARY Further, after the wash out period animals were treated with Simvastatin for 12 TR:TREATMENT_SUMMARY days. #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Oxylipins, endocannabinoids, bile acids and fatty acids were isolated using a SP:SAMPLEPREP_SUMMARY Waters Ostro Sample Preparation Plate (Milford, MA). Lung and trachea samples SP:SAMPLEPREP_SUMMARY were aliquoted (~40-60mg) into 2mL polypropylene tubes and spiked with a 5 µL SP:SAMPLEPREP_SUMMARY anti-oxidant solution (0.2 mg/ml solution BHT/EDTA in 1:1 MeOH:water) and 10 μL SP:SAMPLEPREP_SUMMARY 1000nM analytical deuterated surrogates. A total of 50 µL of methanol, 550µL SP:SAMPLEPREP_SUMMARY isopropanol w/ 10mM ammonium formate & 1% formic acid and 100 uL water were SP:SAMPLEPREP_SUMMARY added and the tube was placed in a Geno/Grinder for 30 sec before being SP:SAMPLEPREP_SUMMARY centrifuged at 10,000g for 5 min at room temp. The supernate was then SP:SAMPLEPREP_SUMMARY transferred into the plate wells and samples were eluted into glass inserts SP:SAMPLEPREP_SUMMARY containing 10 μL 20% glycerol by applying a vacuum at 15 Hg for 10 min. Eluent SP:SAMPLEPREP_SUMMARY was dried by speed vacuum for 35 min at the medium BP setting, before switching SP:SAMPLEPREP_SUMMARY to an aqueous setting for an additional 35 min. Once dry, samples were SP:SAMPLEPREP_SUMMARY re-constituted with the internal standard 1-cyclohexyl ureido, 3-dodecanoic acid SP:SAMPLEPREP_SUMMARY (CUDA) and 1-Phenyl 3-Hexadecanoic Acid Urea (PHAU) at 100 nM (50:50 MeOH:CAN), SP:SAMPLEPREP_SUMMARY vortexed 1 min, transferred to a spin filter (0.1 µm, Millipore, Billerica, SP:SAMPLEPREP_SUMMARY MA), centrifuged for 3 min at 6ºC at <4500g (rcf), before being transferred to SP:SAMPLEPREP_SUMMARY 2 mL LC-MS amber vials. Extracts were stored at -20ºC until analysis by SP:SAMPLEPREP_SUMMARY UPLC-MS/MS. The internal standard was used to quantify the recovery of surrogate SP:SAMPLEPREP_SUMMARY standards. #CHROMATOGRAPHY CH:CHROMATOGRAPHY_TYPE Reversed phase CH:INSTRUMENT_NAME Waters Acquity CH:COLUMN_NAME Aquity C18 BEH 1.7µm 100mm x 2.1mm column CH:FLOW_GRADIENT See protocol/methods file CH:FLOW_RATE 0.25 mL/min CH:COLUMN_TEMPERATURE 60 °C CH:SOLVENT_A 0.1% acetic acid CH:SOLVENT_B 90% ACN / 10% IPA CH:INTERNAL_STANDARD See protocol/methods file CH:RETENTION_TIME See protocol/methods file CH:SAMPLE_INJECTION 5 µL CH:ANALYTICAL_TIME 20 min CH:WEAK_WASH_SOLVENT_NAME 20% methanol, 10% isopropanol CH:WEAK_WASH_VOLUME 600 µL CH:STRONG_WASH_SOLVENT_NAME 50:50 Acetonitrile:Methanol CH:STRONG_WASH_VOLUME 600 µL #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:MS_COMMENTS - MS:INSTRUMENT_NAME ABI Sciex 6500 QTrap MS:INSTRUMENT_TYPE Triple quadrupole MS:MS_TYPE ESI MS:ION_MODE NEGATIVE #MS_METABOLITE_DATA MS_METABOLITE_DATA:UNITS Concentration (nM) MS_METABOLITE_DATA_START Samples Zeki R 74 Zeki R 28 Repl Avg. Zeki R 48 Zeki R 68 Zeki R 40 Zeki R 95 Zeki L 74 Zeki L 48 Zeki L 28 Repl Avg. Zeki L 95 Zeki L 40 Zeki L 68 Zeki T 74 Zeki T 48 Zeki T 28 Repl Avg. Zeki T 40 Zeki T 68 Zeki T 95 Factors Tissue:Right Lung | Treatment:Control Tissue:Right Lung | Treatment:Control Tissue:Right Lung | Treatment:Control Tissue:Right Lung | Treatment:Simvastatin Tissue:Right Lung | Treatment:Simvastatin Tissue:Right Lung | Treatment:Simvastatin Tissue:Left Lung | Treatment:Control Tissue:Left Lung | Treatment:Control Tissue:Left Lung | Treatment:Control Tissue:Left Lung | Treatment:Simvastatin Tissue:Left Lung | Treatment:Simvastatin Tissue:Left Lung | Treatment:Simvastatin Tissue:Trachea | Treatment:Control Tissue:Trachea | Treatment:Control Tissue:Trachea | Treatment:Control Tissue:Trachea | Treatment:Simvastatin Tissue:Trachea | Treatment:Simvastatin Tissue:Trachea | Treatment:Simvastatin 6-keto PGF1a 1.18 8.37 1.18 0.4 0.19 1.97 2.76 1.62 16.05 2.95 0.47 0.97 2.85 0.75 1.62 2.09 1.86 4.57 TXB2 2.39 23.75 3.13 1.52 0.67 6.08 22.2 2.04 42.6 6.97 1.04 2.52 13.5 2.99 17.85 4.41 13.3 8.21 PGE1 2.04 13.15 1.58 1.74 0.32 3.8 25.8 2.09 12.4 4 0.44 4.1 7.49 2.69 1.84 4.51 7.04 11.7 PGE2 52.3 234.5 29.9 21.7 5.87 71.8 340 25.7 259.5 105 9.54 54.8 61 29.6 25.95 33.8 53 104 15-Keto PGE2 3.36 6.12 4.3 1 0.76 2.83 24.2 5.79 8.28 2.27 1.66 2.52 6.64 4.97 6.29 4.31 8.05 5.81 PGD2 51.4 368 40.8 49.4 45.6 107 194 6.75 333 92.7 1.95 91.3 56.6 2.59 28.05 55.9 19.5 109 15-deoxy PGJ2 0.8 10.31 0.08 0.19 0.11 0.99 11.4 0.48 7.51 1.78 0.3 1.45 2.84 0.79 1.23 1 1.57 3.58 PGF2a 11.3 60.85 11.5 7 3.98 15.3 28.3 6.92 60 20 5.74 18.3 25.3 4.13 8.97 8.54 14.5 16.8 11-HETE 14.9 60.95 15.1 11.3 4.92 21.3 29.5 10 68.4 27.1 5.09 17.6 17 5.71 13.4 10 16.6 21.6 Lipoxin A4 9.26 11.53 11.1 5.14 0.94 9.08 2.34 6.85 19.3 14.6 0.86 3.89 3.93 2.51 1.99 3.06 4.38 8.58 6-trans-LTB4 6.7 7.41 20.9 10.8 1.86 8.71 6.04 9.24 10.19 11.8 1.3 10.7 4.69 1.74 3.51 4.68 3.93 13 5_15-DiHETE 8.1 2.3 2.6 1.06 0.66 0.72 1.54 0.44 2.9 0.45 0.69 1.08 0.35 0.29 0.41 0.7 0.38 1.5 8_15-DiHETE 88.8 54.15 110 99.2 16.1 57.5 29.2 38.9 66.25 60.3 12.3 96.3 15.4 6.14 5.45 16.6 21.4 35 9_12_13-TriHOME 87.2 65.15 291 168 37.1 99.8 51.3 135 56.7 109 27.7 135 77.9 54.4 100 91.9 104 206 9_10-e-DiHO 8.42 40 179 19.8 7.98 79.9 23.2 52.5 28.4 19.6 14 84.6 9.78 22.8 13.15 25.1 11.8 85.8 12_13-DiHOME 1.49 1.17 5.31 1.89 3.57 3.24 1.48 2.31 1.41 2.49 4.15 2.27 1.89 2.24 1.38 6.92 2.07 2.5 9_10-DiHOME 2.53 1.75 7.96 3.24 6.05 4.62 1.85 3.24 1.96 4.71 8.24 3.75 2.98 2.67 1.99 8.06 3.35 3.29 15_16-DiHODE 2.29 1.93 6.87 2.15 5.16 3.01 1.42 6.88 1.96 3.87 6.63 2.78 3.88 4.89 2.13 12.9 5.06 2.61 9_10-DiHODE 0.08 0.07 0.2 0.11 0.18 0.21 0.06 0.11 0.04 0.19 0.23 0.14 0.07 0.06 0.05 0.35 0.1 0.13 14_15-DiHETrE 1.25 1.34 1.89 1.59 0.84 1.26 1.18 1.05 1.79 1.53 1.04 1.7 0.69 0.47 0.49 0.95 0.73 0.97 11_12-DiHETrE 0.57 0.78 0.67 0.47 0.67 0.89 0.65 0.55 0.88 1.16 0.9 0.64 0.5 0.34 0.4 0.5 0.39 0.6 8_9-DiHETrE 0.94 0.67 0.78 0.63 0.48 0.7 0.45 0.6 0.91 1.6 0.77 0.52 0.3 0.32 0.22 0.29 0.37 0.3 5_6-DiHETrE 0.45 0.52 0.56 0.14 0.33 0.44 0.3 0.24 0.45 0.6 0.36 0.31 0.1 0.34 0.12 0.31 0.21 0.18 17_18-DiHETE 38.4 16.65 10.6 6.79 14.1 14 6.01 13.3 10.41 19.3 17.8 5.64 5.98 13.9 9.37 35.1 8.04 12.9 19_20-DiHDoPA 2.53 3.13 3.2 1.36 4.39 4.17 1.43 2.6 4.9 4.17 6.77 1.93 1.46 0.54 1.41 1.93 1.17 1.78 13-HODE 4940 1449.5 9160 9840 2030 3830 1590 3010 1580 4820 1180 8570 2000 776 1320 2820 2790 4290 9-HODE 42.2 69.2 97.9 105 44.9 84.4 38.6 37.9 71.7 86.9 49.6 106 73.9 25.7 66.9 115 93.5 145 13-HOTE 266 46.4 408 587 82.8 275 80 178 44.45 375 55 467 151 32.2 69.7 199 208 358 9-HOTE 0.31 0.15 0.83 0.67 1.02 1.16 0.4 0.24 0.22 1.17 1.04 0.81 0.43 0.86 0.27 0.91 0.6 0.55 20-HETE 13 17.35 4.88 7.72 5.76 8.43 4.58 5.53 37.85 22.3 8.08 15.1 0.64 0.81 2.71 0.13 0.67 1.27 15-HETE 310 781.5 403 369 130 456 258 181 872 595 72.2 388 230 130 236.5 150 293 290 12-HETE 8790 8110 11700 8230 1920 7670 4610 5220 10800 10100 1670 9820 3030 1450 2350 2850 3500 6110 9-HETE 6.68 7.27 6.73 5.19 2.36 3.37 3.4 3.84 9.29 5.27 1.06 7.32 2.13 0.7 2.06 2.1 2.07 2.5 8-HETE 87.9 165.75 70.8 45 11.6 98.9 49.9 49.7 223 114 11.1 45.9 34.5 28.9 24.15 24.9 49.8 62.1 5-HETE 6.64 15.7 6.38 3.73 2.94 7.47 15.2 7.6 31.15 8.64 4.27 5.86 13.3 4.07 12.35 8.71 8.98 17.1 15-HEPE 115 349 145 110 40.2 205 92.5 84 160.5 337 36.7 173 35.9 27.5 25.35 32.3 67 52.7 12-HEPE 288 509.5 604 408 79.2 510 302 261 356.5 748 78.3 554 53.5 38.1 46.55 71.1 111 193 9-HEPE 7.53 6.9 7.8 3.07 1.94 6.34 5.64 5.59 9.67 9.64 1.69 5.37 0.78 0.35 0.39 0.85 1.58 2.85 5-HEPE 0.25 2.11 0.74 0.54 0.52 1.77 2.93 0.96 3.32 1.84 0.64 0.7 0.63 0.52 0.88 0.77 1.12 0.76 17-HDoHE 136 302 252 147 104 302 117 124 294 437 81.6 254 203 111 279 210 224 326 14-HDoHE 2000 2245 3590 2890 867 2520 1270 1400 2430 3130 754 3630 1200 762 1080 1170 1720 2420 4-HDoHE 1.59 0.58 0.96 0.35 0.59 1.16 0.68 2.09 2.39 1.51 0.64 1.72 3.03 0.9 4.71 1.65 1.69 6.93 9_10-EpO 13.9 13.85 44.1 11 15.7 13.3 13.8 18.6 16.95 14.9 27.5 15.6 10.9 6.99 6.96 13.3 11.4 24.1 12(13)-EpOME 6.47 7.3 8.68 11.6 18.8 13.7 6.44 7.59 6.51 12.1 19.4 14.6 8.36 9.66 5.71 17.3 13.1 9.88 9(10)-EpOME 8.97 7.49 11.8 11.2 19.7 15 7 8.2 7.86 12.3 20.3 14.9 9.64 10.8 5.26 16.9 13.8 10.7 12(13)-Ep-9-KODE 7.17 4.43 19.9 12.5 6.84 16.9 5.37 17.1 6.12 9.81 14.5 13.1 12.2 9.2 9.08 32.9 14.8 32.9 15(16)-EpODE 0.88 0.59 1.16 0.98 2.49 1.31 0.6 0.7 0.66 1.5 3.46 1.09 0.65 0.68 0.82 2.77 1.64 1.44 12(13)-EpODE 0.35 0.16 0.36 0.64 0.59 0.64 0.39 0.2 0.21 0.75 0.71 0.56 0.38 0.33 0.05 0.32 0.48 0.33 9(10)-EpODE 1.16 0.97 4.17 4.74 2.98 2.38 1.32 3.02 0.83 2.11 2.46 3.74 1.56 1.93 1.71 3.68 3.08 3.19 14(15)-EpETrE 2.63 5.56 3.19 1.3 1.94 3.05 4.81 1.94 6.26 2.78 2.51 3.37 3.61 3.77 2.4 2.31 3.36 2.68 11(12)-EpETrE 2.08 4.34 2.76 0.89 1.85 2.58 2.65 1.82 3.87 2.7 1.39 2.07 2.24 2.45 1.59 1.73 1.51 1.35 8(9)-EpETrE 2.63 5.07 3.22 1.04 1.9 2.51 1.91 2.52 4.15 2.29 1.57 2.83 2.32 3.31 11.92 4.78 3.25 5.32 19(20)-EpDPE 0.19 1.13 1.04 0.05 0.26 1.1 0.47 0.36 1.49 1.93 1.77 0.29 1.11 1.48 1.1 1.19 0.87 0.76 13-KODE 79.1 21.85 220 249 52 79.8 31.1 160 27.3 73.5 42.5 189 82.9 72.2 120 175 145 180 9-KODE 39.8 34.7 80.4 47.9 41.6 56.2 30.7 40.3 38.85 59 52.6 60.8 59.6 31.5 43.05 98 65.3 78.8 15-KETE 10.7 15.25 8.7 7.16 4.77 7.34 5.34 9.57 14 11.7 3.28 10.8 11 8.4 9.1 10.9 10.1 4.13 5-KETE 3.59 3.38 2.73 1.46 1.69 2.65 4.08 2.5 4.7 3.52 2.28 2.16 4.58 1.23 5.5 3.95 3.14 4.66 10-Nitrooleate 13.9 4.18 12.5 11.2 19.7 10.2 4.58 11.4 11.3 5.65 16.3 7.03 11.1 0.75 11.59 16.5 16.7 2.57 PGE3 0.55 9.54 0.43 0.28 0.28 4.08 10.4 1.04 7.85 4.08 0.77 1.56 0.98 0.21 0.37 0.23 0.96 1.59 LTB4 LTB5 Resolvin D1 12_13-DiHODE 14_15-DiHETE 17(18)-EpETE 14(15)-EpETE 11(12)-EpETE 16(17)-EpDPE 15-HpETE screen 12-HpETE screen 5-HpETE screen MS_METABOLITE_DATA_END #METABOLITES METABOLITES_START metabolite_name 6-keto PGF1a TXB2 PGE1 PGE2 15-Keto PGE2 PGD2 15-deoxy PGJ2 PGF2a 11-HETE Lipoxin A4 6-trans-LTB4 5_15-DiHETE 8_15-DiHETE 9_12_13-TriHOME 9_10-e-DiHO 12_13-DiHOME 9_10-DiHOME 15_16-DiHODE 9_10-DiHODE 14_15-DiHETrE 11_12-DiHETrE 8_9-DiHETrE 5_6-DiHETrE 17_18-DiHETE 19_20-DiHDoPA 13-HODE 9-HODE 13-HOTE 9-HOTE 20-HETE 15-HETE 12-HETE 9-HETE 8-HETE 5-HETE 15-HEPE 12-HEPE 9-HEPE 5-HEPE 17-HDoHE 14-HDoHE 4-HDoHE 9_10-EpO 12(13)-EpOME 9(10)-EpOME 12(13)-Ep-9-KODE 15(16)-EpODE 12(13)-EpODE 9(10)-EpODE 14(15)-EpETrE 11(12)-EpETrE 8(9)-EpETrE 19(20)-EpDPE 13-KODE 9-KODE 15-KETE 5-KETE 10-Nitrooleate PGE3 LTB4 LTB5 Resolvin D1 12_13-DiHODE 14_15-DiHETE 17(18)-EpETE 14(15)-EpETE 11(12)-EpETE 16(17)-EpDPE 15-HpETE screen 12-HpETE screen 5-HpETE screen METABOLITES_END #END